| Signifor (pasireotide) / Recordati |
| Active, not recruiting | 4 | 126 | Europe | Hydrocortisone, Pasireotide | Helsinki University Central Hospital | Pancreatic Fistula, Pancreatic Neoplasms | 01/19 | 12/29 | | |
NCT01794793 / 2013-000267-84: Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies |
|
|
| Completed | 4 | 337 | Europe, Canada, Japan, US, RoW | Pasireotide, SOM230; Signifor, Cabergoline, dostinex, Pasireotide LAR | RECORDATI GROUP | Cushing's Disease, Acromegaly, Neuroendocrine Tumors, Pituitary Tumors, Ectopic ACTH Secreting (EAS) Tumors, Dumping Syndrome, Prostate Cancer, Melanoma Negative for bRAF, Melanoma Negative for nRAS | 07/23 | 07/23 | | |
| Active, not recruiting | 3 | 226 | Europe, Canada, US, RoW | Lutathera, AAA601, 30 mg Octreotide long acting repeatable (LAR) (Sandostatin LAR Depot), SOM230, 2.5% Lys-Arg sterile amino acid solution, High dose 60 mg octreotide long-acting repeatable | Advanced Accelerator Applications | Gastro-enteropancreatic Neuroendocrine Tumor | 07/23 | 10/27 | | |
NCT06784752: Study to Evaluate the Efficacy and Safety of [^177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET |
|
|
| Not yet recruiting | 3 | 240 | NA | [^177Lu]Lu-DOTA-TATE, Octreotide LAR, SOM230 | Novartis Pharmaceuticals | Somatostatin Receptor Positive (SSTR+), Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) | 06/28 | 07/32 | | |
2006-004080-55: Stepwise Medical Treatment of Cushing’s Disease: a prospective open label multi-center trial with SOM230 mono- and combination therapy with dopamine agonists and ketoconazole |
|
|
| Ongoing | 2 | 16 | Europe | SOM230, Dostinex, Ketoconazole, SOM230B, Dostinex, Nizoral, Dostinex, Nizoral | Erasmus MC | The medical condition to be investigated is Cushing\'s disease which is caused by an ACTH producing pituitary adenoma | | | | |
2012-003939-27: Objective evaluation of the effects of pasireotide on gastrointestinal and colorectal transit times, rectal wall properties, and postprandial response in patients with carcinoid diarrhea Undersøgelse af pasireotids effekt på transittiden gennem tarmen, endetarmens egenskaber samt respons efter fødeindtag hos patienter med diare grundet en neuroendokrin tumor |
|
|
| Ongoing | 2 | 15 | Europe | Signifor 0.6 mg s.c., Signifor 0.6 mg s.c. | Klaus Krogh, Novartis, Aarhus University | Patients with neuroendocrine tumors and carcinoid diarrhea | | | | |
2019-002507-18: Efficacy and feasibility of pasireotide to reduce clinically relevant digestive leakage after complete cytoreductive surgery (CRS) plus Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) for peritoneal carcinomatosis Evaluation de la faisabilité et de l’efficacité d’un traitement par pasireotide dans la réduction du taux de fistules digestives sévères après chirurgie de cytoréduction complète suivie de chimio-hyperthermie intra-péritonéale pour carcinose péritonéale |
|
|
| Not yet recruiting | 2 | 217 | Europe | Pasireotide, Solution for injection, Signifor 0.9mg solution for injection | Gustave Roussy, PHRC | Primary and secondary peritoneal malignancies Tumeurs primaires et secondaires du péritoine, peritoneal malignancies Tumeurs du péritoine, Diseases [C] - Cancer [C04] | | | | |
PASIREOCHIP, NCT04826432 / 2019-002507-18: Pasireotide to Reduce Clinically Relevant Digestive Leakage After Complete Cytoreductive Surgery (CRS) Plus Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) for Peritoneal Carcinomatosis |
|
|
| Terminated | 2 | 6 | Europe | Pasireotide 0.9 MG/ML, Saline water | Gustave Roussy, Cancer Campus, Grand Paris, PHRC | Peritoneal Carcinomatosis | 02/24 | 02/24 | | |
NCT06295952: A Study of Pasireotide in People With Prolactinoma |
|
|
| Recruiting | 2 | 10 | US | Pasireotide, SF-36 and HADS | Memorial Sloan Kettering Cancer Center, Recordati Pharmaceutical company | Prolactin-Producing Pituitary Tumor | 02/27 | 02/27 | | |
PAMSARC, NCT06456359: Pasireotide as Maintenance Treatment in Synovial Sarcoma and Desmoplastic Small Round Cell Tumor |
|
|
| Recruiting | 2 | 28 | Europe | Signifor, ATC-Code: H01CB05 | University Hospital Heidelberg | Desmoplastic Small Round Cell Tumor, Synovial Sarcoma | 10/27 | 10/28 | | |
| Recruiting | 2 | 72 | Europe, US | Pasireotide Diaspartate, Pasireotide | RECORDATI GROUP | Post-Bariatric Hypoglycemia | 04/25 | 04/26 | | |
NCT02835131: Compassionate Use of SOM230 for Hyperinsulinemic/Hypoglycemia |
|
|
| No Longer Available | N/A | | US | Pasireotide, Signifor, SOM230 | Montefiore Medical Center | Congenital Hyperinsulinism | | | | |
NCT02310269: Long Term Safety and Efficacy of Pasireotide s.c. in Patients With Cushing's Disease |
|
|
| Completed | N/A | 152 | Europe, Canada, US, RoW | Pasireotide, Signifor | RECORDATI GROUP | Cushings Disease | 07/23 | 07/23 | | |
RAPSODIA, NCT06597383: The RApid Switch From 1st Generation Somatostatin Analogues to PaSireOtiDe In Acromegaly |
|
|
| Recruiting | N/A | 100 | Europe | | IRCCS San Raffaele, University of Turin, Italy, University of Padova, Fondazione Policlinico Universitario Agostino Gemelli IRCCS | Acromegaly | 11/24 | 11/24 | | |
